Necati Zavrak

Necati Zavrak

Auto-generated profile, based on publicly available information

Necati Zavrak

Department of Periodontology, Faculty of Dentistry, Pamukkale University, Denizli, Türkiye

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 July 2025 in BMC Oral Health
Verified
Journal Article
Open access
PDF file
AAAysan Lektemur Alpan
Aysan Lektemur Alpan
AKAlper Kızıldağ
Alper Kızıldağ
ÖÖÖzlem Özmen
Özlem Özmen
NZNecati Zavrak
Necati Zavrak
ZÖZeynep Özdoğan
Zeynep Özdoğan
AAAysun Akpınar
Aysun Akpınar
This study evaluated the effects of local and systemic Metronidazole (MTZ) on bone healing in infected mandibular defects using a rat model. Thirty Wistar rats were divided into Control, Local MTZ (L-MTZ), and Systemic MTZ (S-MTZ) groups. Mandibular defects were treated with xenograft mixed saliva from periodontitis patients. Bone regeneration was evaluated using micro-CT and histological analyses. Bone morphogenic protein-2 (BMP-2), alkaline phosphatase (ALP), receptor activator of nuclear factor kappaB ligand (RANKL), osteocalcin (OCN), and beta-catenin (β-catenin), high sensitivity C-reactive protein (hs-CRP) levels evaluated. Increased bone formation and reduced osteoclast counts were detected in the L-MTZ group compared to the Control. β-catenin expression was significantly higher in the L-MTZ group, BMP-2 and Runx2 levels were elevated in both L-MTZ and S-MTZ groups. ALP and OCN levels were the highest in the L-MTZ group, with no significant difference between the L-MTZ and S-MTZ groups. hs-CRP levels were significantly lower in MTZ-treated groups. Micro-CT analysis revealed the highest bone volume/total volume (BV/TV) ratio in the S-MTZ group among all groups. Local MTZ application enhanced bone regeneration by promoting osteoblast activity, activating β-catenin and BMP-2/Runx2 signaling, and reducing inflammation. Systemic MTZ also improved bone healing, particularly in volumetric aspects.

29 September 2025 in BMC Oral Health
Verified
Journal Article
Open access
PDF file
AKAlper Kızıldağ
Alper Kızıldağ
AAAysan Lektemür Alpan
Aysan Lektemür Alpan
ZÖZeynep Özdoğan
Zeynep Özdoğan
OOOzlem Ozmen
Ozlem Ozmen
NZNecati Zavrak
Necati Zavrak
MTMithat TERZİ
Mithat TERZİ
Abaloparatide is a second-generation osteoporosis drug that prevents bone loss and stimulates bone fromation. This study evaluated the effects of abaloparatide treatment on alveolar bone loss (ABL) in osteoporotic rats with periodontitis by immunohistochemical and microcomputed tomography (micro-CT) in rats with periodontitis and osteoporosis. Forty adult female rats were divided into five equal groups: non-ligated (controls), periodontitis (P), periodontitis + osteoporosis (PO), PO treatment with 10 µg/kg abaloparatide (PO-10), and PO treatment with 80 µg/kg abaloparatide (PO-80). Bilateral ovariectomy was conducted in the osteoporosis groups. Three weeks after ovariectomy, experimental periodontitis was induced via Ligature. Abaloparatide was performed at the same time as the induction of experimental periodontitis. All rats were sacrificed at 30 days. ABL was determined via micro-CT and histological analyses. Bone morphogenetic protein 2 (BMP-2), alkaline phosphatase (ALP), receptor ligand for nuclear factor-kappa B (RANKL), osteocalcin (OCN), osteoprotegerin (OPG), and collagen 1 (Col-1) were evaluated immunohistochemically. In addition, the levels of C-terminal telopeptide of type I collagen (CTX), which is related to bone turnover, were analyzed. Periodontitis with osteoporosis significantly increased ABL in the PO versus the P group. Abaloparatide treatment significantly reduced ABL in the treatment groups and significantly increased BMP-2, ALP, Col-1, OPG, OCN, and CTX levels. In particular, 80 µg/kg abaloparatide treatment significantly modulated the RANKL, OPG, and CTX levels in the PO-80 group. The micro-CT results indicated that abaloparatide treatment significantly enhanced the percentage of bone, trabecular thickness, trabecular number, and bone surface density. Abaloparatide treatment regulates bone formation dose-dependently by decreasing ABL in rats with periodontitis and osteoporosis.